Clinical Trial Site Startup Supply Checklist

A clinical trial site preparing for first-patient-in usually has the protocol-specific pieces accounted for: the investigational product, the central-lab collection kits, the sponsor-issued diaries and questionnaires. What gets missed more often is everything outside that sponsor-supplied stream — the general clinical consumables and emergency-response supplies a site has to have in place regardless of which protocol it’s running, and stocked in a way that survives a monitor’s or auditor’s attention if any of it touches a subject’s safety record. This is that checklist: what to stock beyond the protocol kit, and why the paperwork around it looks different from ordering supplies for a routine clinic day.

Two supply streams, not one

Trial sites end up managing two genuinely different supply chains at once, and conflating them is where startup checklists go wrong.

The first is the protocol-specific stream: the investigational medicinal product (IMP) itself, any comparator or placebo, and anything the protocol or lab manual names explicitly — specific specimen-collection tubes, a designated ECG cable, a central-lab-supplied kit for a particular assay. This stream is sponsor-controlled. ICH E6(R2) Section 5.14 puts the obligation on the sponsor to confirm the investigator has received IP appropriately and to ensure written procedures exist at the site for receipt, storage, dispensing, and return — and E6(R3) restates the same responsibility at Section 2.10.1, resting with the investigator for accountability and handling once product arrives. Substituting anything in this stream — a different tube type, a different device lot than the one qualified for the study — is not a stocking decision, it’s a protocol deviation. See Clinical Trial Supply Management for the IMP side of this in full (GMP manufacturing, IRT/IWRS, cold chain, accountability logs) and Major Protocol Deviation for what happens when the wrong supply gets used anyway.

The second is the general clinical stream: the consumables and equipment the site itself is responsible for stocking, the same way any clinical operation is — PPE, phlebotomy and IV supplies not named by the protocol, wound-care materials, and the emergency-response equipment needed to manage an adverse event safely. Sponsors do not ship this. A monitor reviewing readiness at the Site Initiation Visit checks that it’s in place, but building and maintaining it is the site’s own operational responsibility, funded out of the site’s own budget rather than the trial’s supply chain. See Site Initiation Visit (SIV) Checklist for the full readiness review this feeds into.

This page is about the second stream — what belongs in it, and how its documentation obligations differ from an ordinary clinic’s supply closet.

General clinical consumables every site needs before first-patient-in

None of the following is protocol-specific — a site needs it whether it’s running an oncology infusion trial or a behavioral-intervention study with minimal physical contact, because it supports the clinical encounter itself, not the intervention being studied.

• Personal protective equipment — gloves, gowns, and eye/face protection sized and available for every staff role that has contact with blood, other potentially infectious materials (OPIM), or sharps. This isn’t a trial-specific requirement; it flows from OSHA’s Bloodborne Pathogens Standard, 29 CFR 1910.1030, which applies to any site handling human blood or OPIM independent of what research is underway. The standard requires a written exposure control plan, PPE and engineering/work-practice controls, free hepatitis B vaccination for at-risk staff, and a defined post-exposure follow-up procedure — a research site’s exposure control plan needs to name trial-related procedures (venipuncture, IV starts, specimen handling) explicitly, not just describe the clinic’s routine care.
• Sharps disposal — puncture-resistant, closable sharps containers at point of use, sized for trial visit volume, not just clinic volume; a site running frequent PK draws or injections needs more sharps capacity than its baseline clinic traffic would suggest.
• Phlebotomy and specimen-handling supplies not specified by the protocol — alcohol preps, tourniquets, gauze, bandages, general-purpose collection tubes for anything not sent to a central lab under a named kit. The moment a protocol or lab manual specifies an exact tube type, additive, or vendor for a given draw, that item moves into the protocol-specific stream above and substitution risk applies.
• General vital-signs and monitoring supplies — blood pressure cuffs in the sizes the study population actually needs, thermometers, pulse oximeters, a working scale. Baseline and routine visit vitals are collected on essentially every trial regardless of therapeutic area.
• Wound-care and dressing supplies — gauze, adhesive and non-adherent dressings, tape, for routine post-injection or post-procedure site care. See Wound Care Supply Selection Guide for selection detail across dressing types.
• General IV-start supplies — catheters, extension sets, tape, and securement for hydration or line access that supports the visit but isn’t the IMP administration set itself (which, for an infused IMP, is typically protocol-specified). See IV Catheter Gauge Selection and Infusion Supplies and Pump Selection.

Emergency response supplies for adverse events

This is the category new sites most often under-scope, because it doesn’t map neatly to a line item on a study budget. ICH E6 has never treated it as optional: the guideline places responsibility on the investigator to ensure adequate medical care is available to a subject for any adverse event related to trial participation, including managing it as a medical emergency where warranted — a principle carried through both E6(R2) and the current E6(R3) revision. What that means operationally is that a site’s emergency-response readiness has to be sized to the actual risk profile of what it’s running, not to a generic minimum.

• Anaphylaxis/allergic-reaction response — this is the sharpest example of risk-based sizing. A site running infusion or injection trials (biologics, monoclonal antibodies, contrast-requiring imaging visits) needs a stocked, checked anaphylaxis response capability at every dosing visit: epinephrine, antihistamines, and the equipment to manage an airway, sourced and stocked as part of the site’s own emergency formulary — separate from, and never substituted with, the investigational product itself. A site running a low-risk observational or survey-based protocol has a much smaller version of this obligation, but essentially never zero, since any blood draw carries a (small) vasovagal or allergic-reaction risk.
• AED and basic resuscitation equipment — automated external defibrillator, bag-valve-mask, oxygen source, appropriate for the setting and staff training level. See Buying an AED for Your Facility and Stocking an Emergency Trauma Response Kit for what a facility-grade emergency kit actually needs to contain and how to select equipment for it.
• A stocked, OSHA-adequate general first aid kit — the baseline every clinical space needs regardless of trial risk level. See Building an OSHA-Compliant Workplace First Aid Kit for stocking detail.
• A written emergency response plan naming who responds, what’s called (site emergency services, on-call PI/sub-I), and how the response gets documented as source data tied to the resulting AE or SAE report — not just a supply list but the procedure for using it. This is the piece a monitor or inspector actually checks; having the kit and having a documented, rehearsed procedure for using it are treated very differently at a Site Initiation Visit or a Bioresearch Monitoring inspection.

Hospital-based sites operating under Joint Commission or equivalent accreditation typically already run scheduled checks of code-cart and emergency-equipment readiness under their facility’s Environment of Care program; a trial-dedicated research space that sits outside that infrastructure — a standalone research clinic, a mobile or decentralized site — has to build an equivalent check into its own SOPs rather than inherit one, since nothing forces it to exist by default.

Why this differs from routine clinic stocking

A general medical clinic restocks supplies against inventory par levels and expiration dates, full stop — if a box of gauze expires unused, it gets discarded and reordered, with no further consequence. A trial site’s general supply stream carries the same restocking discipline plus a layer of GCP documentation weight that routine clinic supplies never accumulate, for two specific reasons:

1. Anything used during an adverse event becomes part of the trial record. If a subject has an infusion reaction and the site administers epinephrine from its emergency stock, that action — what was given, the lot, the time, the response — has to be captured as source documentation tied to the AE report, not just logged in the clinic’s general medication administration record. ICH E6(R2) Section 8 defines essential documents as those that permit evaluation of trial conduct and data quality; an emergency intervention that affects a safety outcome falls inside that evaluation even though the epinephrine itself was never protocol-supplied. See Source Documentation and Adverse Event Reporting to the IRB for how that record has to read.
2. Substitution risk runs through supplies a routine clinic would treat as interchangeable. A clinic can swap gauze brands or tube vendors freely. A trial site cannot do this silently for anything the protocol or lab manual specifies by type, lot, or vendor — a substitution there is a protocol deviation regardless of whether the substitute item was clinically equivalent. The practical implication for startup stocking is to sort every consumable into one of the two streams described above before ordering, not after a monitor flags a mismatch. Items in the general stream can be sourced on ordinary procurement terms; items that cross into the protocol-specific stream need the exact specification the protocol names, tracked the way IP itself is tracked.

The Trial Master File and site-level essential document set (see Trial Master File (TMF)) is where this distinction shows up structurally: IP accountability logs, temperature logs, and protocol-specified-supply records belong in the TMF/ISF; a site’s general PPE, first-aid, and emergency-kit inventory typically lives in the site’s own facility/EHS records instead, reviewed for readiness but not filed as a trial essential document — unless something from that stock ends up implicated in an AE, at which point the specific item used crosses into the trial record via the source documentation route above.

A startup supply checklist

Before scheduling a Site Initiation Visit, a site coordinator should be able to check each of these as complete and documented:

• Written exposure control plan (29 CFR 1910.1030) updated to name trial-specific procedures, not just routine clinic care
• PPE stocked and sized for every staff role with trial-visit patient contact
• Sharps containers placed and sized for anticipated trial visit volume
• General phlebotomy/IV supplies stocked, with a clear written line between these and any protocol-specified collection materials
• Vital-signs and monitoring equipment on hand and within calibration/maintenance schedule
• Anaphylaxis/emergency-reaction response stocked and checked, sized to the protocol’s actual risk profile (infusion/injection studies need more than survey-based studies)
• AED present, inspected, and staff trained to the facility’s required level
• General first aid kit stocked to a recognized standard and inspection-dated
• Written emergency response procedure in place, naming responders and the documentation path back to the AE/SAE record
• Every consumable sorted into “general stream” (site-procured, facility record) vs. “protocol-specific stream” (sponsor-specified, tracked in the TMF/ISF) before the first order goes in

Sourcing note

The general-stream items above — PPE, IV/phlebotomy consumables, dressings, and general first-aid stock — are ordinary clinical procurement, not part of the sponsor’s trial supply chain, so sites typically source them the same way they’d source any clinic’s general inventory. CASRAI’s sister medical-supply company, LAC’s first aid kit category, IV catheter category, and medical dressings category carry general clinical stock in this range, if a site is setting up procurement from scratch rather than working through an existing facility contract.

Frequently asked questions

Does the sponsor ever pay for a site’s general clinical supplies?

Not typically. Sponsors fund and ship the protocol-specific stream (IP, comparator, central-lab kits, protocol-named devices) because that stream is theirs to control for data integrity and regulatory reasons. General clinical consumables and emergency-response readiness are usually treated as a site overhead cost, sometimes partially offset through per-visit or per-patient payments in the clinical trial agreement, but the site is expected to already have this infrastructure in place independent of any single study — it’s baseline clinical capability, not a study deliverable.

Does every protocol need the same emergency-response stocking?

No. Emergency-response readiness should be sized to the actual risk profile of the intervention and population — an infusion trial of a biologic with known hypersensitivity risk needs a more robust anaphylaxis and resuscitation capability at every dosing visit than a low-risk observational study does. The protocol’s safety and risk sections, plus the sponsor’s site-qualification and monitoring expectations, should drive how much a given site scales this up beyond its baseline.

Who checks that a site’s general supplies are ready before enrollment starts?

Readiness is confirmed at the Site Initiation Visit, usually by the CRA or sponsor representative, as part of the broader SIV agenda — though the SIV verifies readiness rather than building it, so everything needs to already be in place beforehand. See the Site Initiation Visit (SIV) Checklist for the full category-by-category review.

Do general supplies need lot-number tracking the way investigational product does?

Not as a blanket rule. Lot-level tracking is a trial-essential-document requirement for IP and for anything the protocol or lab manual specifies by type/lot/vendor. A general first-aid or PPE item only becomes trial-relevant documentation if it’s actually used in managing an adverse event, at which point what was used, when, and its effect need to be captured as source data tied to that AE — not because the item itself was ever protocol-tracked, but because the safety event it supported now is.